-
ASCO 2023 BCO Coverage
Check out our continuing coverage of the 2023 American Society of Clinical Oncology Annual Meeting here:
-
Breaking Research News from Breastcancer.org
Breastcancer.org strives to bring you updates on the latest breast cancer research through its Research News program. Medical experts at Breastcancer.org provide easy-to-understand summaries of what the research means for YOU. Favorite this thread to get notifications on all the breaking news about current breast cancer…
-
Dana Farber 2022-2023 EMBRACE MBC Virtual Forum Series
Hi all! We wanted to share with you a helpful series of five free online virtual forums about promising areas of research and treatment in metastatic breast cancer hosted by Dana Farber's 2022-2023 EMBRACE MBC program. You can access the recordings here: * Welcome Session | 2022-2023 EMBRACE MBC Virtual Forum Series *…
-
Podcast: 2023 ASCO Takeaways
-
2023 ASCO abstracts
All abstracts…
-
Breaking Research News from sources other than Breastcancer.org
I watch for research news on breast cancer, treatments, etc., and frequently see interesting articles. There is a topic on BCO called "Breaking Research News from Breastcancer.org." One of the moderators suggested that another topic might be appropriate for posting links and synopses of reports on research found elsewhere.…
-
Identifying the optimal therapeutics ... ER+ & Her2+
Identifying the optimal therapeutics for patients with hormone receptor- positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis https://www.sciencedirect.com/scienc...59702923004428
-
Clinical utility of liquid biopsy in breast cancer: A systematic review
Clinical utility of liquid biopsy in breast cancer: A systematic review DefineMBC™: A clinical experience summary from 25 United States-based cancer centers on the clinical utility of a comprehensive liquid biopsy in metastatic breast cancer https://www.oncology-central.com/wp-...per_1Nov22.pdf
-
List of sequential regimens particular to your condition.
Hello, If there is a program that takes relevant condition (stage, pathology, treatment history, etc) of your illness, and based on current published research (from ASCO, SABCS, ESSO, MBCC, etc), the program generates a list of sequential regimens specific to you. The program continuously update the regimen list as…
-
Podcast: 2022 SABCS Key Take-Aways
2022 SABCS Key Take-Aways Dec 13, 2022 Dr. Stephanie Graff explains the most interesting research presented at the 2022 San Antonio Breast Cancer Symposium. The 2022 San Antonio Breast Cancer Symposium featured five days of research presentations, educational sessions, and posters. The amount of research presented can be…
-
Anyone interested in participating in a paid research study?
Hi All. I am participating in a paid study for breast cancer patients. Here is the info in case anyone is interested. Just send Devi an email if you are interested and she will get back to you to screen you for the study. **********Her email to me ******************** We have quite a range of different things. But we will…
-
BCO Conference Coverage: SABCS 2022
Every December, the San Antonio Breast Cancer Symposium brings together clinicians, researchers, and advocates to discuss the latest breast cancer study results. We're proud to present our coverage below. ***Stay tuned to this thread as more coverage is added!***
-
Research into Targeted Radiotherapy for LeptoMeningeal Mets
I got this info from Metavivor social media and searched for articles on it. Good to see this is happening. Plus Therapeutics Awarded 17.6 Million Dollars from the State of Texas https://www.globenewswire.com/news-release/2022/08/17/2500436/0/en/Plus-Therapeutics-Awarded-17-6-Million-from-State-of-Texas.html “LM is one of…
-
Metformin-Anyone on this trial?
My onc suggested I go on this trial after I finish chemo. Is anyone else on this trial?
-
Podcast: Just Ask: Increasing Diversity in Clinical Trials
Just Ask: Increasing Diversity in Clinical Trials May 27, 2022 Dr. Nadine Barrett discusses why diversity in clinical trials is so important and how the Just Ask program helps address that lack of diversity. Listen to the episode to hear Dr. Barrett talk about: *why diversity in in clinical trials is so important *what the…
-
High dose estrogen therapy for breast cancer
The use of high-dose estrogens for the treatment of breast cancer - PubMed (nih.gov) Abstract Estrogens are known to stimulate the growth of breast cancer but they are also an effective treatment for this disease (this has been termed the 'estrogen paradox'). The fact that estrogens can be an effective treatment for breast…
-
real-world data ... assess cfDNA ... resistance
Use of real-world data (RWD) to assess the utility of cell-free circulating tumor DNA (cfDNA) in identifying resistance to early treatment in advanced breast cancer (aBC) https://meetings.asco.org/abstracts-...tations/209022 Seth Andrew Wander, Caroline Weipert, Jiemin Liao, Nicole Zhang, Pedram Razavi Organizations…
-
Which BC patients will benefit from metformin?
Primarily people with metabolic syndrome can benefit from including metformin in their BC treatment regimen, according to this article.…
-
Clinical Trial for Metastatic TNBC Now Recruiting
CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer Description This phase I trial tests the safety, side effects, and best dose of CF33-hNIS-antiPDL1 in treating patients with triple negative breast cancer that has spread to other places in the body (metastatic). CF33-hNIS-antiPDL1 is an…
-
A couple of informative articles on management of ER+ MBC
Some of the esoteric (brain fog at the moment) but useful information are in the detail which lead to chasing down references for more. Nguyen Standard of Care in Hormone Receptor–Positive Metastatic Breast Cancer: Can We Improve the Current Regimens or Develop Better Selection Tools?…
-
Risk of Peritoneal CA post Prophylactic Salpingo-Oophorectomy
https://www.medpagetoday.com/hematologyoncology/ot... The presence of serous tubal intraepithelial carcinoma (STIC) at the time of risk-reducing salpingo-oophorectomy (RRSO) significantly increased the risk of peritoneal carcinomatosis (PC) in BRCA1/2 mutation carriers, a large meta-analysis showed. The risk of PC…
-
Biodegradable gel boosts immune systems attack
https://www.sciencedaily.com/releases/2022/04/2204... A new biodegradable gel improves the immune system's ability to keep cancer at bay after tumors are surgically removed. The gel, tested in mice, releases drugs and special antibodies that simultaneously deplete immune-blocking cells called macrophages from the surgical…
-
RXPonder results
Sorry if this is a repeat but navigating this site is a pain in the tuches/butt! https://www.exactsciences.com/newsroom/rxponder-st... Snippet of info: RxPONDER showed a different effect of chemotherapy based on Recurrence Score® results for postmenopausal and premenopausal women. Postmenopausal women with Recurrence Score…
-
Metformin ....
https://www.sciencedaily.com/releases/2022/02/2202... Computer drug simulations offer warning about promising diabetes and cancer treatment Metformin highly effective in targeting diabetes and some cancers but potentially dangerous with others
-
Molecular Biomarkers Predictive of Resistance to CDK4/6
Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer https://ascopubs.org/doi/10.1200/PO.21.00002 Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have revolutionized the treatment of hormone-positive metastatic breast cancers (mBCs). They are currently…
-
BCO Research: Breast Cancer Patients Use of Cannabis
We're pleased to share with you our new Breastcancer.org Research published in Cancer magazine: Breast Cancer Patients' Use of Cannabis
-
ERBB2-Low Efficacy of CDK 4/6 HR+, ERBB2- BC
ERBB2-Low Expression and Efficacy of CDK 4/6 Inhibitor in HR-Positive, ERBB2-Negative Breast Cancer Kelvin K. H. Bao, MB, BChir, MA1; Leone Sutanto, MB, ChB1; Shirley S. W. Tse, MB, BS1; et al 8-10 minutes November 5, 2021 The Association of ERBB2-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in…
-
Studies recruiting participants
Many of us want to be able to do SOMETHING...ANYTHING.... about this dreadful disease. If we are not practitioners or bench scientists, then communication, advocacy, studies and clinical trails may seem like all we can do ... aside from charitable giving or rendering to direct aid to those in need. So... I am starting this…
-
BC mets in an.models reduced by mdifyng tumor electrical prop.
https://www.sciencedaily.com/releases/2022/01/2201... In normal cells, electrical voltage patterns provide a blueprint for orderly growth. But with cancer, the opposite happens. Marked by a breakdown in the normal electrical patterns generated by the cells, they lose their specialized functions, start expanding into a…
-
liquid biopsy for early monitoring and outcome prediction
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer https://www.nature.com/articles/s41523-021-00319-4...
-
Podcast: Top Research Presented at the 2021 SABCS
Top Research Presented at the 2021 San Antonio Breast Cancer Symposium December 21, 2021 Dr. Sara Tolaney is chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women's Cancers at the Dana-Farber Cancer Institute, as well as associate professor of medicine at Harvard Medical…
-
Podcast: Breast Cancer Research at ESMO 2021
Breast Cancer Research at ESMO 2021 October 21, 2021 Dr. Brian Wojciechowski practices medical oncology in Delaware County, Pennsylvania at Riddle, Taylor, and Crozer hospitals and also serves as Breastcancer.org's medical adviser. A native of South Philadelphia, he trained at Temple University School of Medicine and…
-
Racial, Ethnic Minorities Underrepresented in Cancer Research
Racial, Ethnic Minorities Underrepresented in Cancer Research November 12, 2021 Black, Hispanic, American Indian, and Alaskan Native people are vastly underrepresented in research studies on breast, prostate, lung, and colorectal cancer. Read more...